Augie’s Quest announced the 11th annual ‘Tradition of Hope’ gala event will be held Oct. 15 at the Beverly Hilton Hotel to raise funds for amyotrophic lateral sclerosis (ALS) research. Augie’s Quest is a cure-driven nonprofit effort dedicated to finding treatments and a cure for ALS. The effort…

AB Science has been invited to present new preclinical studies on masitinib in the treatment of amyotrophic lateral sclerosis (ALS) at four international meetings this year. These were the main findings from the series of preclinical studies: Proof of concept data from the preclinical trials of masitinib showed that the investigational drug “targets…

A new study led by researchers with the United Nations (UN) has projected that the number of cases of amyotrophic lateral sclerosis (ALS) will increase by 69% over the next 25 years, primarily due to population ageing. According to the study “Projected increase in amyotrophic lateral sclerosis…

The U.S. U.S. Food and Drug Administration (FDA) has accepted Mitsubishi Tanabe Pharma’s new drug application (NDA) for edaravone as a treatment for amyotrophic lateral sclerosis (ALS). A decision regarding the intravenous treatment is expected by June 16, 2017, based on the U.S. Prescription Drug User Fee Act. If it is…

AB Science announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug status to masitinib, a potential treatment for amyotrophic lateral sclerosis (ALS). Masitinib is an orally administered tyrosine kinase inhibitor targeting mast cells and macrophages, key immune system cells, that works to…

Rapporteurs appointed by the European Medicines Agency (EMA) have recommended that AB Science SA’s combined treatment ‘masitinib with riluzole’ in the treatment of adults with amyotrophic lateral sclerosis (ALS) should be filed for conditional marketing authorization. AB Science specializes in developing and marketing protein kinase inhibitors (PKIs), a class of targeted proteins…

The American Academy of Neurology Annual Meeting(AAN 2016), in Vancouver, British Columbia, featured significant advances in the understanding and treatment of amyotrophic lateral sclerosis (ALS). Among presentations at the April event, were ALS focused studies conducted by Dr. Sara van Mossevelde, Dr. Adriano Chio, Dr. Lindsey Hayes, Dr.

A bill that would waive the five-month waiting period for Social Security Disability Insurance (SSDI) for people with amyotrophic lateral sclerosis (ALS) — legislation supported by the ALS Association during its recent National ALS Advocacy Day in Washington, D.C. — has been introduced into the U.S. Congress. Called the ALS Disability Insurance Access…

Ammar Al-Chalabi, a professor of Neurology and Complex Disease Genetics at King’s College London, was presented with the  Sheila Essey Award at a special session of the recent American Academy of Neurology (AAN) Annual Meeting dedicated to amyotrophic lateral sclerosis (ALS) research. He was selected to receive the $50,000 award by both the ALS Association…

The ALS Association and the American Academy of Neurology (AAN) announced the 2016 winners of its Clinical Research Training Fellowship and Clinician-Scientist Development Award in amyotrophic lateral sclerosis (ALS) research. The awards are given annually to young clinicians who propose promising and innovative ALS studies, both to foster their professional development…